Drugs / SHR8008
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05074602 | Sep 2021 → Sep 2023 | vulvovaginal candidiasis | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04956419 | Apr → Sep 2021 | vulvovaginal candidiasis | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR8008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05074602 ↗ |
| Route | Oral | “once daily for 2 days(Day 1 and Day 2),oral” NCT04956419 ↗ |